Amgen Hires Independent Academic Group to Recheck Data for Rare Disease Drug Under FDA Scrutiny

Amgen Inc. engaged an independent academic organization to reevaluate data for a rare disease drug that US regulators are seeking to withdraw from the market. According to Bloomberg, the review is aimed at reassessing the drug’s data as the company faces efforts by US regulators to pull it.